RankingsPricing
  1. US-listed companies
  2. PTC THERAPEUTICS, INC.
  3. Raw

PTC THERAPEUTICS, INC.PTCT

Market cap
$5.9B
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Net loss attributable to common stockholders-51,573,575-94-170-142-79-128-252-438-524-559-627-363
Depreciation and amortization----182632436412923776
Non-cash operating lease expense-------6710108
Non-cash royalty revenue related to sale of future royalties-------2234993182
Noncash Interest Expense, Liability Related to Sale of Future Royalties-------327873105207
Intangible asset impairment---------33218160
Change in valuation of contingent consideration-----194823-0-26-128-4
Tangible asset impairment-----------4
Loss on sale of fixed assets------------4
Gain on lease terminations-----------2
Gain on lease modification-----------5
Gain on sale of priority review voucher-----------100
Unrealized (gain) loss on ClearPoint Equity Investments---------6-4-28
Unrealized loss on ClearPoint convertible debt security-------19-8-6-3-2
Unrealized (gain) loss on marketable securities - equity investments-------142-833
Realized loss for the sale of ClearPoint Equity Investment-----------1-
Realized loss on ClearPoint convertible debt security------------1
Realized gain on redemption of marketable securities- equity investments----------4-
Issuance of Stock for Milestone Payment----------30-
Disposal of asset------------0
Deferred income taxes----00-960-34-47-56
Amortization of (discounts) premiums on investments, net--2-2-2-102-0-5-2213
Amortization of debt issuance costs--0001112221
Loss on extinguishment of debt-----------56-
Share-based compensation expense81934353133427010411010275
Unrealized foreign currency transaction (gains) losses, net----1001257-47-131410
Non cash foreign currency remeasurement loss on intercompany loan----------17--
Inventory, net----663-2-278-6
Prepaid expenses and other current assets760,50122-122913155245-99
Trade and royalty receivables, net-56,09137151230-121045482-2
Deposits and other assets-48,0420-001118103-5-12
Accounts payable and accrued expenses51717424442771462848-33
Other liabilities------14-4-7-5-212
Deferred revenue-----7-1-8-41-15
Payments on contingent consideration----------10--2
Net cash used in operating activities----104-10-28-99-194-251-357-158-108
Purchases of fixed assets845,7325323714182832287
Proceeds from sale of fixed assets-----------28
Proceeds from sale of priority review voucher-----------150
Purchases of marketable securities - available for sale-------1033353174608
Purchases of marketable securities - equity investments1562482248581694941,440210233859
Proceeds from Sale of Debt Securities, Available-for-Sale--------84340522550
Proceeds from Sale and Maturity of Marketable Securities2910720619217590156944411313248
Sale and redemption of ClearPoint Equity Investments----------3-
Proceeds from settlement of Clearpoint convertible debt security-----------10
Acquisition of product rights and licenses----7783238571209268
Net cash provided by (used in) investing activities---10413-43-387-562219290-17744
Proceeds from exercise of options-191211187017152429
Proceeds from Stock Plans----23456665
Repayment of senior secured term loan------1228--300-
Debt extinguishment costs related to senior secured term loan-------1--82-
Proceeds From Sale of Future Royalties-------650--1,000242
Debt issuance costs related to secured term loan--5------110-
Proceeds from Issuance of Secured Debt----40----300--
Repayment of Convertible Notes---------150--
Payments on contingent consideration obligation-----------18
Payment of finance lease principal-------182111
Proceeds from stock purchase agreement---------50--
Net cash provided by financing activities---14413261366921168646256
Effect of exchange rate changes on cash----------33-7
Net increase in cash and cash equivalents------126-79-1999314185
Cash paid for interest------8101018366
Income Taxes Paid, Net2,077-0112226851418
Unrealized (loss) gain on marketable securities, net of tax-------1-301-0
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability------1777136-6
Acquisition of product rights and licenses-----611142233550
Fixed asset additions through tenant improvement allowance-----------19
Debt issuance costs related to senior secured term loan---------0--
Capital Expenditures Incurred but Not yet Paid-------1-0-0